Intervention Protocol

You have free access to this content

Effect of testing for cancer on cancer- and venous thromboembolism (VTE)-related mortality and morbidity in patients with unprovoked VTE

  1. Lindsay Robertson1,*,
  2. Roshan Agarwal2,
  3. Su Ern Yeoh3

Editorial Group: Cochrane Peripheral Vascular Diseases Group

Published Online: 19 NOV 2013

DOI: 10.1002/14651858.CD010837


How to Cite

Robertson L, Agarwal R, Yeoh SE. Effect of testing for cancer on cancer- and venous thromboembolism (VTE)-related mortality and morbidity in patients with unprovoked VTE (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 11. Art. No.: CD010837. DOI: 10.1002/14651858.CD010837.

Author Information

  1. 1

    The Freeman Hospital, Department of Vascular Surgery, Newcastle upon Tyne, UK

  2. 2

    Imperial College London, Department of Oncology, London, UK

  3. 3

    University of Edinburgh, College of Medicine and Veterinary Medicine, Edinburgh, UK

*Lindsay Robertson, Department of Vascular Surgery, The Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, High Heaton, Newcastle upon Tyne, NE7 7DN, UK. lindsay.robertson@nuth.nhs.uk. lindsay.robertson@ed.ac.uk.

Publication History

  1. Publication Status: New
  2. Published Online: 19 NOV 2013

SEARCH

 

Background

  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Appendices
  6. Contributions of authors
  7. Declarations of interest
  8. Sources of support
 

Description of the condition

Venous thromboembolism (VTE) is the collective term for the clinical conditions deep vein thrombosis (DVT) and pulmonary embolism (PE). DVT is the formation of a blood clot (thrombus) in a deep vein, predominantly in the legs. Symptoms include pain, tenderness, erythema and swelling of the affected leg. PE occurs when part or all of the thrombus breaks off (embolises) and travels up to the lungs, blocking the pulmonary arteries. Symptoms of PE include breathlessness and chest pain (Blann 2006).

Guidelines published by the UK National Institute for Health and Clinical Excellence (NICE) recommend that patients with a suspected DVT should be risk stratified using the Wells score, undergo a D-dimer test and have a proximal leg vein ultrasound scan based on the risk of DVT (NICE 2012a). Similarly, patients with a suspected PE should be assessed using the Wells PE risk score, D-dimer and a computed tomography pulmonary angiogram (CTPA) depending on the PE risk. The NICE guidelines recommend that anticoagulant therapy with low molecular weight heparin (LMWH) should be administered in the interim until these diagnostic investigations are carried out if leg ultrasound is expected to take longer than four hours, or if a CTPA cannot be performed immediately (NICE 2012a). Patients with confirmed VTE should receive LMWH or fondaparinux for at least the initial five days and, except for cancer patients, all others also started on a vitamin K antagonist. The LMWH should be stopped when the international normalised ratio (INR) has been above 2 for at least 24 hours. Vitamin K antagonists should be continued for at least three months in all patients. In patients with an unprovoked VTE consideration should be given to extending anticoagulation beyond three months based on an assessment of the risk of VTE recurrence and complications of anticoagulation. However, patients with cancer-associated VTE should be treated with LMWH from initial diagnosis for six months, and considered for continuation of anticoagulation with either LMWH or a vitamin K antagonist based on the status of the underlying cancer and risks of anticoagulation (NICE 2012a). More recently, rivaroxaban has been used for the treatment of DVT and prevention of recurrent DVT and PE (NICE 2012b). Guidelines by NICE recommend that rivaroxaban should be administered at a dose of 15 mg twice daily for the first 21 days followed by a continual dose of 20 mg once daily to prevent recurrence. Evidence from the EINSTEIN-DVT study showed that, in a subgroup of patients with active cancer, rivaroxaban was less effective than LMWH at preventing VTE recurrence (hazard ratio 1.32, 95% confidence interval (CI) 0.06 to 32.3) but was associated with fewer major bleeding events (Einstein Investigators).

The difference in management of patients with a cancer-associated VTE is due to their significantly higher risk of VTE recurrence, which is estimated to be three time higher than in patients with no cancer-associated VTE (Levitan 1999). The underlying pathophysiology of cancer and thrombosis involves a complex process of several mechanisms including a "release of inflammatory cytokines, activation of the clotting system, expression of haemostatic proteins on tumour cells, inhibition of natural anticoagulants and impaired fibrinolysis" as described by Rodrigues 2010. Activation of the clotting system has also been implicated in cancer-associated angiogenesis, tumour metastasis and aggressiveness. Indeed patients with cancer and an associated VTE have a poorer overall prognosis compared to patients without a VTE, with a 12% one-year survival from the diagnosis of VTE (Kakkar 1969; Ruiz 2003).

A proportion of patients with VTE have no underlying or immediately apparent cause and the VTE is referred to as idiopathic or unprovoked. Unprovoked VTE can often be the first clinical manifestation of underlying malignancies such as cancer of the blood, kidney, ovary, pancreas, stomach and lung (Bick 1978; Kakkar 2003; Lee 2003a; Prandoni 1997; White 2005). Results from a Swedish prospective cohort study of almost 62,000 patients determined that the standardised incidence ratio of a cancer diagnosis within the first two years of an unprovoked VTE was 4.4 (Baron 1998), and there was an overall absolute incidence of cancer of 11% (NICE 2012a). A UK study of 339 patients with a first episode of an unprovoked VTE measured that the relative risk (RR) of cancer-related mortality at two years was 0.52 (95% CI 0.10 to 2.75) while the RR for early-stage cancer detection was 3.21 (95% CI 0.88 to 11.79) (Piccioli 2004).

Patients who present with an apparent unprovoked VTE, therefore, have a significant underlying risk of malignancy or cancer-associated VTE, with significant implications for the management of the VTE itself (three months vitamin K antagonist versus six months LMWH), the prognosis related to risk of VTE recurrence and the precipitating cancer. This has raised the question of whether patients with an unprovoked VTE should be investigated for an underlying cancer. Some authors refer to this as 'screening for cancer' although this is somewhat misleading, as screening refers to the investigation of asymptomatic patients. Instead, patients with VTE are better regarded as presenting with symptoms suggestive of an underlying cancer and the aim of investigations is to better refine the diagnosis of VTE based on the underlying cause, so that the patient may receive a more accurate diagnosis and appropriate treatment for their VTE. In this context, VTE represents a symptom of a disease rather than a diagnosis per se. So to what extent should patients with an unprovoked VTE be investigated for a potential underlying cancer?

 

Description of the intervention

The NICE guidelines on venous thromboembolic disease (NICE 2012a) recommend that all patients diagnosed with a first episode of unprovoked VTE (DVT or PE) should undergo a history and physical examination directed to detecting an underlying malignancy, and further tests guided by the history and examination including blood tests (complete blood count, serum calcium and liver function tests), urinalysis and chest X-ray. If none of these initial investigations confirm signs and symptoms of cancer then further tests including an abdomino-pelvic computerised tomography (CT) scan (and a mammogram for women) are recommended in patients over 40 years (NICE 2012a).

 

Laboratory tests

Complete blood count is a test that measures the number of red cells, white cells and platelets in the blood. This test can diagnose certain conditions including polycythaemia, anaemia, leukocytosis, leukopenia, thrombocytosis and thrombocytopenia, all indicators for various cancers (Tefferi 2005).

Serum calcium tests indicate hypercalcaemia, an elevated calcium level in the blood greater than 2.6 mmol/L. Hypercalcaemia affects between 10% to 40% of cancer patients at some time during their disease (Mundy 1997). The type of malignancies associated with hypercalcaemia include solid tumours such as breast and squamous cell lung cancer and haematologic malignancies such as multiple myelomas (Muggia 1990).

The liver is a common site of metastases. Liver function tests are a group of tests used to determine evidence of liver damage. Liver function tests look for levels of enzymes, proteins and compounds made by the liver including alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (gamma GT), ammonia, bilirubin, albumin, prothrombin and fibrinogen (Limdi 2003).

Urinalysis is a simple test used to check urine for blood, protein and other substances. Blood in the urine (haematuria) is found in 80% to 90% of patients with bladder cancer (Fritsche) while high levels of protein in the urine (proteinuria) is found in 50% to 60% of patients with renal cell carcinoma (Motzer 1996).

Tumour markers refer to substances found in the blood, urine or body tissues which, when elevated, are indicative of cancers including breast, colorectal, gastrointestinal, ovarian, lung and pancreatic cancers as well as glioma, lymphoma and leukaemia. The most commonly used tumour marker is the prostate-specific antigen (PSA) blood test used to detect prostate cancer in men (Sturgeon 2009).

Sputum cytology refers to the analysis of sputum to detect the presence of a pulmonary malignancy and is most commonly used to detect lung cancer cells.

Polymerase chain reaction (PCR) based tests are relatively new tests used to identify and measure circulating tumour DNA and RNA markers extracted from serum, plasma, saliva and urine. Initial evidence suggests that using this combination of DNA and RNA markers may diagnose over 80% of lung cancer cases (Bremnes 2005).

 

Imaging tests

Chest X-rays can show evidence of metastases, effusions or the primary tumour and are often the first diagnostic evaluation for patients with suspected lung cancer.

A CCT scan of the abdomen and pelvis is used for diagnosis and in combination with chest CT to determine the stage of the cancer. The CT scan takes pictures of the body from different angles and gives a series of cross sections to build up a detailed picture of inside the body showing the tumour size and location as well as its proximity to major organs.

A mammogram is an X-ray of the chest which is used to detect calcification, very early non-invasive cancers such as ductal carcinoma in situ (DCIS) and breast cancer. In the UK mammograms are routinely offered as an NHS breast screening programme to all women aged 50 to 70 years.

 

How the intervention might work

The interventions for detecting an underlying cancer will enable a diagnosis of cancer-associated VTE to be made or excluded. This will enable the patient to receive appropriate anticoagulation with LMWH or vitamin K antagonist, for three or six months, and for any underlying cancer to be treated without the need for additional symptoms to emerge before it is diagnosed. It has been shown that the combination of tests recommended by NICE detects cancer in approximately 10% of patients with a first episode of unprovoked VTE with no prior cancer diagnosis (Piccioli 2004).

 

Why it is important to do this review

The pharmacological management of VTE in patients with and without cancer is considerably different, both in terms of choice and duration of anticoagulation. Therefore, an appropriate cancer diagnosis would ensure that patients received the optimal form and duration of anticoagulation which, in turn, could reduce the overall population VTE recurrence rate and associated morbidity. Establishing whether a patient with an apparently unprovoked VTE has an underlying cancer is important since this may lead to cancer diagnosis at an earlier, potentially curative stage, avoiding the risk of cancer progression whilst waiting for additional symptoms. This may in turn lead to improvements in cancer-related mortality and morbidity. To date, no systematic review has been conducted to measure the effectiveness of testing for cancer in patients with an unprovoked VTE. This review will provide evidence as to whether such tests for underlying cancer, followed by appropriate alteration in the management or treatment of VTE, or both, are effective in reducing morbidity (VTE recurrence) and mortality (VTE and cancer-associated).

 

Objectives

  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Appendices
  6. Contributions of authors
  7. Declarations of interest
  8. Sources of support

  1. To determine whether testing for undiagnosed cancer in patients with a first episode of unprovoked VTE (DVT or PE) is effective in reducing cancer mortality and morbidity.
  2. To determine whether testing for undiagnosed cancer in patients with a first episode of unprovoked VTE (DVT or PE) is effective in reducing VTE-related mortality and morbidity.
  3. To determine which tests for cancer are most useful.

 

Methods

  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Appendices
  6. Contributions of authors
  7. Declarations of interest
  8. Sources of support
 

Criteria for considering studies for this review

 

Types of studies

Randomised and quasi-randomised trials in which patients with an unprovoked VTE were allocated to receive different tests for cancer or no further tests. We will primarily look at randomisation within three months of a VTE, as used in the SOMIT trial (Piccioli 2004). However, we will also include trials where randomisation occurred at different time points. We will include this as a subgroup analysis. We will include published studies and studies in progress if preliminary results are available. Non-English studies will also be eligible for inclusion in the review.

 

Types of participants

Patients with a first episode of unprovoked VTE (DVT or PE) with no pre-existing or clinically apparent cancer diagnosis.

 

Types of interventions

Tests for cancer (e.g. complete blood count, serum calcium, liver function test, urinalysis, chest X-ray, all forms of computed tomography imaging, mammogram, tumour markers, sputum cytology, ultrasonography, positron emission tomography scan and colonoscopy) versus no tests for cancer or alternative tests, followed by appropriate treatment for cancer or change in VTE treatment regime, or both. We will not include studies where these tests are routinely used in all arms of the studies. However, we will include any study that focuses on some other aspect of care than cancer only if the test for cancer is the subject of randomisation.

 

Types of outcome measures

 

Primary outcomes

  1. Non-cancer-related mortality (death due to some cause other than cancer or cancer-related treatment).
  2. Cancer-related mortality (defined as death due to a malignant disease itself, or death due to complications of treatments or procedures to diagnose or treat the cancer).
  3. VTE-related mortality (fatal PE). PE diagnosed "on the basis of a lung scan indicating a high probability of its presence, as indicated by the presence of new or enlarged areas of segmental perfusion defects with ventilation–perfusion mismatch; an abnormal perfusion scan with documentation of new or recurrent deep-vein thrombosis; the presence of non-enhancing filling defects in the central pulmonary vasculature on helical computed tomography; a finding of intraluminal filling defects on pulmonary angiography; or evidence of fresh pulmonary embolism at autopsy" (Lee 2003b). Fatal PE including probable fatal PE and unexplained sudden death will be used if reported as defined by individual studies.

 

Secondary outcomes

  1. VTE-related morbidity (e.g. frequency of recurrent VTE). Recurrent DVT diagnosed if a previously compressible proximal venous segment or segments could no longer be compressed on ultrasonography or if there were constant intraluminal filling defects in two or more projections on venography. Unequivocal extension of the thrombus required for the diagnosis of recurrence if the results were abnormal on previous testing (Lee 2003b).
  2. Complications of anticoagulation (e.g. warfarin versus LMWH-associated bleeding). We will report on major bleeding and minor bleeding if reported in the included studies. Major bleeding includes bleeding associated with death, bleeding at a critical site (intracranial, intraspinal, intraocular, retroperitoneal or pericardial area), bleeding resulting in a need for a transfusion of at least two units of blood, or bleeding leading to a drop in haemoglobin of at least 2.0 g per decilitre (Lee 2003b). Minor bleeding includes any other bleeding.
  3. Side effects of cancer tests (e.g. radiation exposure, bleeding, as defined in included studies).
  4. Characteristics of diagnosed cancer (e.g. primary tumour, stage, localised (curable) versus advanced (palliative) as defined in included studies).
  5. Time to cancer diagnosis, as defined in included studies.
  6. Frequency of an underlying cancer diagnosis (that is the number of times cancer has been diagnosed through screening following an unprovoked VTE as defined in included studies).
  7. Patient satisfaction (if assessed in individual studies, we will report results descriptively using the definition provided by the trialists).

 

Search methods for identification of studies

There will be no restriction on date or language of publication.

 

Electronic searches

The Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator (TSC) will search the Specialised Register and the Cochrane Central Register of Controlled Trials (CENTRAL), part of The Cochrane Library, (www.thecochranelibrary.com). See Appendix 1 for details of the search strategy which will be used to search CENTRAL. The Specialised Register is maintained by the TSC and is constructed from weekly electronic searches of MEDLINE, EMBASE, CINAHL and AMED, and through handsearching relevant journals. The full list of the databases, journals and conference proceedings which have been searched, as well as the search strategies used, are described in the Specialised Register section of the Cochrane Peripheral Vascular Diseases Group module in The Cochrane Library (www.thecochranelibrary.com).

The TSC will search the following trial databases for details of ongoing and unpublished studies:

 

Searching other resources

We will search the reference lists of relevant articles retrieved by electronic searches for additional citations. Furthermore, we will search conference proceedings of the following societies to find abstracts: the International Society for Thrombosis and Haemostasis (ISTH) (from 2003 to present) and the American Society for Haematology (ASH) (2004 to present).

 

Data collection and analysis

 

Selection of studies

One review author (LR) will use the selection criteria to identify trials for inclusion. The second review author (SEY) will independently confirm this selection and any disagreements will be resolved by discussion.

 

Data extraction and management

Two review authors (LR, SEY) will independently extract the data. We will record information about the trial design, VTE definition and investigations to confirm diagnosis, baseline characteristics of patients and tests for cancer. We will record non cancer-related mortality, cancer-related mortality and VTE-related mortality data as the primary outcome measures. We will collect information on VTE-related morbidity (e.g. frequency of recurrent VTE), complications of anticoagulation (e.g. warfarin versus LMWH-associated bleeding), side effects of cancer tests (e.g. radiation exposure, bleeding), characteristics of diagnosed cancer (e.g. primary tumour, stage, localised (curable) versus advanced (palliative)), time to cancer diagnosis, frequency of an underlying cancer diagnosis and patient satisfaction in accordance with the secondary outcome measures. We will contact authors of included studies for further information if clarification is required. We will resolve any disagreements in data extraction and management by discussion.

 

Assessment of risk of bias in included studies

Two review authors (LR, SEY) will independently use The Cochrane Collaboration's tool (Higgins 2011) for assessing risk of bias for each of the included studies. The tool provides a protocol for judgements on sequence generation, allocation methods, blinding, incomplete outcome data, selective outcome reporting and any other relevant biases. We will judge each of these domains as either high, low or unclear risk of bias according to Higgins 2011 and provide support for each judgement. We will present the conclusions in a 'Risk of bias' table. Any disagreements will be resolved by discussion.

 

Measures of treatment effect

We will base analysis on intention-to-treat data from the individual clinical trials. The majority of outcomes are binary measures (mortality, morbidity, complications, side effects, characteristics of diagnosed cancer, frequency of an underlying cancer diagnosis). For these outcomes we will compute odds ratios (ORs) using a random-effects model and calculate the 95% confidence intervals (CI) of the effect sizes. For time to cancer diagnosis we will compute hazard ratios (HR) while for patient satisfaction we will report results descriptively (Deeks 2011).

 

Unit of analysis issues

The unit of analysis within each trial will be the individual participant.

 

Dealing with missing data

We will seek information about dropouts, withdrawals and other missing data and, if not reported, we will contact the study authors.

 

Assessment of heterogeneity

We will assess heterogeneity between the trials by visual examination of the forest plot to check for overlapping CIs, using the Chi2 test for homogeneity with a 10% level of significance and we will use the I2 statistic to measure the degree of inconsistency between the studies. An I2 result of over 50% may represent moderate to substantial heterogeneity (Deeks 2011).

 

Assessment of reporting biases

We will assess reporting biases such as publication bias using funnel plots. There are many reasons for funnel plot asymmetry and we will consult the Cochrane Handbook for Systematic Reviews of Interventions to aid the interpretation of the results (Sterne 2011).

 

Data synthesis

The review authors will independently extract the data. One review author (LR) will input the data into RevMan (RevMan 2012). A second review author (SEY) will cross-check data entry and we will resolve any discrepancies by consulting the source publication.

We will use a random-effects model to meta-analyse the data. We will stratify analyses according to the individual test being assessed. If data are available in individual studies, we will stratify further analysis similarly to the combination of tests used in the SOMIT trial (Piccioli 2004).

If the I2 statistic for heterogeneity is over 75%, we will not perform a meta-analysis.

 

Subgroup analysis and investigation of heterogeneity

  1. DVT or PE
  2. Cancer site
  3. Treatment post-investigation with vitamin K antagonist or LMWH
  4. Duration of anticoagulation (e.g. three or six months)
  5. Age and gender of patients (comparing those in age/gender groups for national screening programmes to those not in these age/gender groups)
  6. Time of randomisation after VTE diagnosis (within three months compared with after three months)

 

Sensitivity analysis

We will perform sensitivity analysis by excluding studies that are judged to be at high risk of bias.

 

Appendices

  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Appendices
  6. Contributions of authors
  7. Declarations of interest
  8. Sources of support
 

Appendix 1. CENTRAL search strategy


#1MeSH descriptor: [Thrombosis] this term only

#2MeSH descriptor: [Thromboembolism] this term only

#3MeSH descriptor: [Venous Thromboembolism] this term only

#4MeSH descriptor: [Venous Thrombosis] explode all trees

#5(thrombo* or thrombus* or embol*):ti,ab,kw  (Word variations have been searched)

#6MeSH descriptor: [Pulmonary Embolism] explode all trees

#7PE or DVT or VTE:ti,ab,kw  (Word variations have been searched)

#8((vein* or ven*) near thromb*):ti,ab,kw  (Word variations have been searched)

#9blood clot:ti,ab,kw  (Word variations have been searched)

#10blood flow stasis:ti,ab,kw  (Word variations have been searched)

#11vein stasis* or "venous stasis":ti,ab,kw  (Word variations have been searched)

#12#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 

#13MeSH descriptor: [Neoplasms] explode all trees

#14malignan*:ti,ab,kw  (Word variations have been searched)

#15*neoplas*:ti,ab,kw  (Word variations have been searched)

#16cancer:ti,ab,kw  (Word variations have been searched)

#17carcinoma* or adenocarcinoma*:ti,ab,kw  (Word variations have been searched)

#18tumour* or tumor*:ti,ab,kw  (Word variations have been searched)

#19#13 or #14 or #15 or #16 or #17 or #18 

#20MeSH descriptor: [Mass Screening] explode all trees

#21MeSH descriptor: [Early Diagnosis] explode all trees

#22screen*:ti,ab,kw  (Word variations have been searched)

#23assess*:ti,ab,kw  (Word variations have been searched)

#24investigat*:ti,ab,kw  (Word variations have been searched)

#25test:ti,ab,kw  (Word variations have been searched)

#26testing:ti,ab,kw  (Word variations have been searched)

#27#20 or #21 or #22 or #23 or #24 or #25 or #26 

#28#12 and #19 and #27 



 

Contributions of authors

  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Appendices
  6. Contributions of authors
  7. Declarations of interest
  8. Sources of support

LR: drafted the protocol, will select studies for inclusion, assess the quality of studies, carry out data extraction, perform data analysis and write the review.
RA: contributed to the protocol and will provide clinical input to the review.
SEY: will select studies for inclusion, assess the quality of the studies and carry out data extraction.

 

Declarations of interest

  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Appendices
  6. Contributions of authors
  7. Declarations of interest
  8. Sources of support

None known.

 

Sources of support

  1. Top of page
  2. Background
  3. Objectives
  4. Methods
  5. Appendices
  6. Contributions of authors
  7. Declarations of interest
  8. Sources of support
 

Internal sources

  • No sources of support supplied

 

External sources

  • National Institute for Health Research (NIHR), UK.
    LR is supported by a programme grant from the NIHR.
  • Chief Scientist Office, Scottish Government Health Directorates, The Scottish Government, UK.
    The PVD Group editorial base is supported by the Chief Scientist Office.
  • National Institute for Health Research (NIHR), UK.
    The PVD Group editorial base is supported by a programme grant from the NIHR.

References

Additional references

  1. Top of page
  2. Abstract
  3. Background
  4. Objectives
  5. Methods
  6. Appendices
  7. Contributions of authors
  8. Declarations of interest
  9. Sources of support
  10. Additional references
Baron 1998
Bick 1978
  • Bick RL. Alterations of hemostasis associated with malignancy: etiology, pathophysiology, diagnosis and management. Seminars in Thrombosis and Hemostasis 1978;5(1):1-26.
Blann 2006
Bremnes 2005
Deeks 2011
  • Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Einstein Investigators
  • EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, et al. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine 2010;363(26):2499-510.
Fritsche
  • Fritsche HA, Grossman HB, Lerner SP, Sawczuk I. National Academy of Clinical Biochemistry Guidelines for the use of tumor markers in bladder cancer. NACB: Practice guidelines and recommendations for use of tumor markers in the clinic. Bladder cancer (3H) (available from http://www.aacc.org/SiteCollectionDocuments/NACB/LMPG/tumor/chp3h_bladder.pdf) (accessed 23 May 2013).
Higgins 2011
  • Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Kakkar 1969
  • Kakkar VV, Flanc C, Howe CT, O'Shea M, Flute PT. Treatment of deep vein thrombosis. A trial of heparin, streptokinase, and Arvin. British Medical Journal 1969;1(5647):806-8, 809-10.
Kakkar 2003
Lee 2003a
  • Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation 2003;107(23 Suppl 1):I17-21.
Lee 2003b
  • Lee AYY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. New England Journal of Medicine 2003;349(2):146-53.
Levitan 1999
  • Levitan N, Dowlati A, Remick SC, Tahsildar HI, Sivinski LD, Beyth R, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999;78(5):285-91.
Limdi 2003
Motzer 1996
Muggia 1990
Mundy 1997
  • Mundy GR, Guise TA. Hypercalcemia of malignancy. American Journal of Medicine 1997;103(2):134-45.
NICE 2012a
  • National Institute for Health and Clinical Excellence. Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing. NICE clinical guideline 144. Issued June 2012. guidance.nice.org.uk/cg144 (accessed 31 October 2013).
NICE 2012b
  • NHS National Institution for Health and Clinical Excellence. Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism. NICE technology appraisal guidance 261. Issued: July 2012. guidance.nice.org.uk/ta261 (accessed 31 October 2013).
Piccioli 2004
Prandoni 1997
  • Prandoni P, Piccioli A. Venous thromboembolism and cancer: a two-way clinical association. Frontiers in Bioscience 1997;2:e12-21.
RevMan 2012
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
Rodrigues 2010
  • Rodrigues CA, Ferrarotto R, Filho RK, Novis YA, Hoff PM. Venous thromboembolism and cancer: a systematic review. Journal of Thrombosis and Thrombolysis 2010;30(1):67-78.
Ruiz 2003
  • Ruiz Y, Caballero P, Caniego JL, Friera A, Olivera MJ, Tagarro D. Prospective comparison of helical CT with angiography in pulmonary embolism: global and selective vascular territory analysis. Interobserver agreement. European Radiology 2003;13(4):823-9.
Sterne 2011
  • Sterne JAC, Egger M, Moher D (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
Sturgeon 2009
  • Sturgeon CM, Lai LC, Duffy MJ. Serum tumour markers; how to order and interpret them. BMJ 2009;339(b3527):852-8.
Tefferi 2005
  • Tefferi A, Hanson CA, Inwards DJ. How to interpret and pursue an abnormal complete blood cell count in adults. Mayo Clinic Proceedings 2005;80(7):923-36.
White 2005
  • White RH, Chew HK, Zhou H, Parikh-Patel A, Harris D, Harvey D, et al. Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Archives of Internal Medicine 2005;165(15):1782-7.